About ActoGeniX
ActoGeniX is a Healthcare company based in Ghent (Belgium) founded in 2006, and was acquired by Precigen in February 2015. Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides. ActoGeniX has raised $57.24 million across 4 funding rounds from investors including Gimv, VIB and Precigen. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology.
Company details
ActoGeniX was founded in 2006 in Ghent, Belgium, within the biotechnology sector. Operations center on the TopAct platform, by which food-grade microbes are modified to produce ActoBiotics, orally administered biopharmaceuticals that express cytokines, enzymes, and antibodies locally in the gastrointestinal tract. Clinical products address oral mucositis and inflammatory bowel disease. The company was acquired by Intrexon Corp. in February 2015.
- Headquarters Ghent, Belgium
- Stage Acquired
- SectorsHealthcare
- Website actogenix.com
- Social LinkedIn X
- Acquired by Precigen (Feb 2015)
Funding Insights of ActoGeniX
ActoGeniX has successfully raised a total of $57.24M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14.04 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.24M
- Total Rounds 4
- Last Round Series B — $14.04M
- First Round $25.8M
(Feb 2007)
- Investors Count 8
All 4 funding rounds of ActoGeniX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $14.04M | Series B | – | – | |
| Feb 2009 | $17.4M | Series A | – | – | |
| Jul 2007 | $4.2M | Grant | – | – | |
| Feb 2007 | $25.8M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in ActoGeniX
ActoGeniX has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Gimv, VIB and Precigen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| saffelberg.com | ||||
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
| baekelandfonds.be | ||||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Aescap is focused on investing in high-growth biotech companies. | aescap.com | Amsterdam, Netherlands | ||
Early-stage funding is provided to innovative founders by Ventech. | ventechvc.com | Paris, France | ||
VIB is recognized as a leading biotechnology research institute. | 1995 | vib.be | Ghent, Belgium | |
A platform for online casino gaming in Belgium is provided. | iwt.be | Belgium | ||
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | 1998 | precigen.com | Germantown, United States |
Investor details for ActoGeniX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ActoGeniX
4 dated milestones of ActoGeniX across 9 years, from founding to its latest funding, stage changes and deals.
- Founded ActoGeniX is founded.
- Funding First funding round of $25.8M.
- Funding Latest funding round, Series B, of $14.0M.
- Exit Acquired by Precigen.
Web traffic of ActoGeniX
The website of ActoGeniX (actogenix.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 159.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Actogenix
Complete news archive for ActoGeniX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ActoGeniX
ActoGeniX was founded in 2006 and raised its 1st funding round 1 year after it was founded.
ActoGeniX is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
ActoGeniX is a funded company, having raised a total of $57.24M across 4 funding rounds to date. The company's 1st funding round was a Series A of $25.8M, raised on Feb 2007.
ActoGeniX was founded in 2006 in Ghent, Belgium, within the biotechnology sector. Operations center on the TopAct platform, by which food-grade microbes are modified to produce ActoBiotics, orally administered biopharmaceuticals that express cytokines, enzymes, and antibodies locally in the gastrointestinal tract. Clinical products address oral mucositis and inflammatory bowel disease. The company was acquired by Intrexon Corp. in February 2015.
ActoGeniX has 9 investors. Key investors include Gimv, VIB, Precigen, Life Sciences Partners, and Saffelberg Investments.
Yes. ActoGeniX was acquired by Precigen in February 2015.